Replies to post #76720 on Ocata Therapeutics Inc fka OCAT

[farviewhill]

Thanks, Wopsal.
Forgot to figure in the Lincoln line in my thinking.

The good news is this, imo, the uplist will signal a major fundamental foundation change for how the stock behaves and is perceived on the Street by sooner than latter in phase 2 attracting some serious institutional buying and dramatically curtail, but not eliminate, the naked shorting and incredible share price manipulation we've been subjected to which has just 'destroyed' the impact of positive developments and rendered the company's share price to that of a windmill going nowhere.

Also, imo, this then puts a more understandable frame of reference to the often posted negative effects of financing dilution, which is is always part and parcel of the nature of a r and d biotech coming of age, as one factors in and realizes the incredibly negative share price 'stranglehold' of the naked shorting as the primary culprit now and in days past.